Medicare proposes to only cover Alzheimer's drug aduhelm for use in clinical trials

(HealthDay)—It’s a move that could severely limit the number of people taking the controversial new Alzheimer’s drug Aduhelm: Medicare on Tuesday proposed to only cover the cost of the pricey medication for people enrolled in approved clinical trials.

This article was originally published on MedicalXpress.com

Read More: